BIBeverley Isherwood

Beverley Isherwood

*This is an algorithmically generated author record based on publicly available information.

Beverley Isherwood has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Large‐scale isolation of human skeletal muscle satellite cells from post‐mortem tissue and development of quantitative assays to evaluate modulators of myogenesis

    by Ian C. Scott, Wendy Tomlinson, Andrew Walding, Beverley Isherwood, Iain G. Dougall

    Background During aging, there is a decreased ability to maintain skeletal muscle mass and function (sarcopenia). Such changes in skeletal muscle are also co-morbidities of diseases including cancer...


  • Open Access

    Live Cell in Vitro and in Vivo Imaging Applications: Accelerating Drug Discovery

    by Beverley Isherwood, Paul Timpson, Ewan J McGhee, Kurt I Anderson, Marta Canel, Alan Serrels, Valerie G Brunton, Neil O Carragher

    Dynamic regulation of specific molecular processes and cellular phenotypes in live cell systems reveal unique insights into cell fate and drug pharmacology that are not gained from traditional fixed endpoint assays. Recent advances in microscopic imaging platform technology combined with the development of novel optical biosensors and sophisticated image analysis solutions have increased the scope of live cell imaging applications in drug discovery. We highlight recent literature examples where live cell imaging has uncovered novel insight into biological mechanism or drug mode-of-action. We survey distinct types of optical biosensors and associated analytical methods for monitoring molecular dynamics, in vitro and in vivo. We describe the recent expansion of live cell imaging into automated target validation and drug screening activities through the development of dedicated brightfield and fluorescence kinetic imaging platforms. We provide specific examples of how temporal profiling of phenotypic response signatures using such kinetic imaging platforms can increase the value of in vitro high-content screening. Finally, we offer a prospective view of how further application and development of live cell imaging technology and reagents can accelerate preclinical lead optimization cycles and enhance the in vitro to in vivo translation of drug candidates.